Bio tech company updates — 4/30/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korea's biotech sector is making headlines on multiple fronts today, from the launch of a unified global expansion body "K-Pharma-Bio One Team" to Samsung Bioepis inking an open innovation deal with China's ATLATL, and Taimei Technology debuting AI-powered clinical research tools at BIO KOREA 2026. The $33B global biosimilar market is also reshaping Korea's pharma giants, with Celltrion and Samsung Bioepis commanding a 53.5% share in Europe.
Key Findings
-
BIO KOREA 2026 is underway, co-hosted by the Korea Health Industry Development Institute (KHIDI) and Chungcheongbuk-do Province, drawing international exhibitors and showcasing global health innovations.
-
Taimei Technology, an AI-driven drug clinical development platform, made its South Korean debut at BIO KOREA 2026 on April 30, 2026, presenting advanced AI-powered clinical research solutions.
-
K-Pharma-Bio One Team was officially launched, with KPBMA, KHIDI, KoreaBio, and KOTRA signing an MOU to create a unified front for global expansion support for Korea's pharmaceutical and biotech industry, ahead of BIO USA 2025.
-
Samsung Bioepis signed an MOU with ATLATL Innovation Center, a China-based bioresearch platform described as one of Asia's largest biotech incubation platforms, expanding its global open innovation efforts.
-
Korea's biosimilar market has hit a significant turning point in 2026, with Celltrion and Samsung Bioepis together holding a 53.5% share of the European biosimilar market. Samsung Bioepis' Stelara biosimilar Pyzchiva became a top-three player in the U.S. ustekinumab market within a single year.
-
Qatar–Korea partnership is expanding from energy into AI, biotech, and chips, as a Qatari government delegation visited Seoul this week to explore new investment areas.
-
Daejeon Technopark is moving to become a global biotech gateway, leveraging the city's long-standing reputation as South Korea's science capital to build a broader international research and commercialization platform.
Details
BIO KOREA 2026 in Full Swing
BIO KOREA 2026, an international bio-health industry convention, kicked off on April 28 and is running through the week. Co-hosted by KHIDI and Chungcheongbuk-do Province, the event is showcasing the latest global health innovations and serving as a magnet for international biotech players.
Among the notable international debuts at the event, Taimei Technology — a leading AI-driven clinical development platform — presented its suite of AI-powered tools designed to streamline drug clinical research. The company's appearance marks its first public foray into the South Korean market.
K-Pharma-Bio One Team: A Unified Industry Front
Korea's pharmaceutical and biotech sector is taking a coordinated approach to international markets. Four major organizations — KPBMA, KHIDI, KoreaBio, and KOTRA — signed an MOU to form the "K-Pharma-Bio One Team," a body aimed at consolidating global expansion support for Korean bio-pharma companies. The initiative comes ahead of BIO USA, one of the world's largest biotech conferences.
Samsung Bioepis Deepens China Innovation Ties
Samsung Bioepis announced it has signed an MOU with ATLATL Innovation Center, one of Asia's largest biotech incubation platforms based in China. The partnership is designed to expand Samsung Bioepis' global open innovation strategy, giving it access to a broader pipeline of early-stage biotech startups and research capabilities.
Korea Biosimilar Market Reaches Global Dominance
The Korea biosimilar market has quietly arrived as a dominant force in the $33 billion global biosimilar landscape. According to Seoulz, Celltrion and Samsung Bioepis together hold a 53.5% share of the European biosimilar market in 2026. Samsung Bioepis' Pyzchiva (a Stelara/ustekinumab biosimilar) has achieved a top-three market position in the United States within just one year of launch — a notable commercial milestone.
Qatar Eyes Korean Biotech for Investment
A delegation from the Qatari government arrived in Seoul this week with a stated intent to expand the historically energy-focused Korea–Qatar partnership into new sectors including biotech, AI, and semiconductors. The visit signals growing international interest in Korea's life sciences ecosystem.
Daejeon Technopark Opens Global Biotech Gateway
Daejeon, widely known as South Korea's science capital, is taking steps to transform its deep research base into a global biotech commercialization platform. Daejeon Technopark is positioning the city as a gateway for international biotech companies and investors looking to tap into Korea's scientific infrastructure.
Sources
K-Biotech 2026: The 3 Korean Startups Big Pharma Can
Korea Biosimilar Market 2026: Inside the $33B Global Wars Reshaping Big Pharma
seoulz.com
manilatimes.net
en.sedaily.com
koreabiomed.com
dongascience.com
koreaherald.com
koreaherald.com
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
